2-((3,4-dimethylphenoxy)methyl)oxirane | 41457-34-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-((3,4-dimethylphenoxy)methyl)oxirane
• 英文别名: 2-(3,4-Dimethyl-phenoxymethyl)-oxirane；2-[(3,4-dimethylphenoxy)methyl]oxirane
• CAS: 41457-34-5
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.231
• InChiKey: ZABVHXJGMITPLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  122.7 °C(Press: 1.3 Torr)
• 密度：
  1.071±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-((3,4-dimethylphenoxy)methyl)oxirane 在 吡啶 、 盐酸 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 4.0h， 生成 TO502-1408 hydrochloride
  参考文献：
  名称：

  Nonracemic Dimethylphenyl Glycerol Ethers in the Synthesis of Physiologically Active Aminopropanols

  摘要：

  Six regioisomeric nonracemic dimethylphenyl glycerol ethers were synthesized by asymmetric dihydroxylation of the corresponding allyl dimethylphenyl ethers. The enantioselectivity of the reaction with o-methyl derivatives was lower (down to 34% ee) than with m-methylphenyl ethers (up to 86% ee). Enantiomeric 3-(3,4-dimethylphenoxy)propane-1,2-diols were used to obtain enantiomerically pure physiologically active amino alcohols and their derivatives.

  DOI：

  10.1134/s1070428019060149
• 作为产物：
  描述：

  3-(3,4-dimethyl-phenoxy)-propane-1,2-diol 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以60%的产率得到2-((3,4-dimethylphenoxy)methyl)oxirane
  参考文献：
  名称：

  Nonracemic Dimethylphenyl Glycerol Ethers in the Synthesis of Physiologically Active Aminopropanols

  摘要：

  Six regioisomeric nonracemic dimethylphenyl glycerol ethers were synthesized by asymmetric dihydroxylation of the corresponding allyl dimethylphenyl ethers. The enantioselectivity of the reaction with o-methyl derivatives was lower (down to 34% ee) than with m-methylphenyl ethers (up to 86% ee). Enantiomeric 3-(3,4-dimethylphenoxy)propane-1,2-diols were used to obtain enantiomerically pure physiologically active amino alcohols and their derivatives.

  DOI：

  10.1134/s1070428019060149

文献信息

• Montmorillonite K10 catalyzed highly regioselective azidolysis of epoxides: A short and efficient synthesis of phenylglycine
  作者：Keshab Ch Ghosh、Isita Banerjee、Surajit Sinha

  DOI：10.1080/00397911.2018.1524494

  日期：2018.11.17

  Abstract A series of β‐hydroxyazides were effectively synthesized from the regioselective ring opening of epoxides by sodium azide using montmorillonite K10 as a novel heterogeneous catalyst in aqueous acetonitrile in good to excellent yields. The utility of this method has been demonstrated by achieving a short synthesis of phenylglycine in 33.5% overall yield. Graphical Abstract

  摘要 以蒙脱石 K10 作为新型多相催化剂，在乙腈水溶液中，通过叠氮化钠对环氧化物的区域选择性开环，有效合成了一系列 β-羟基叠氮化物，收率良好。通过以 33.5% 的总收率实现苯基甘氨酸的短时间合成，证明了该方法的实用性。图形概要
• SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF
  申请人：CAO Bin

  公开号：US20100075994A1

  公开（公告）日：2010-03-25

  The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

  本发明涉及一系列取代二氢和四氢噁唑嘧啶酮，具体地说，涉及一系列式(I)的2-取代-2,3-二氢-噁唑并[3,2-a]嘧啶-7-酮和2-取代-2,3,5,6-四氢-噁唑并[3,2-a]嘧啶-7-酮： 其中p、n、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。本发明还涉及制备这些化合物的方法，包括新颖的中间体。本发明的化合物是代谢型谷氨酸受体（mGluR）的调节剂，特别是mGluR2受体。因此，本发明的化合物在药物制剂中具有用途，特别是在治疗和/或预防各种中枢神经系统疾病（CNS）方面，包括但不限于急性和慢性神经退行性疾病、精神病、癫痫、焦虑、抑郁、偏头痛、疼痛、睡眠障碍和呕吐。
• Imidazolium-based ionic liquid immobilized on functionalized magnetic hydrotalcite (Fe₃O₄/HT-IM): as an efficient heterogeneous magnetic nanocatalyst for chemical fixation of carbon dioxide under green conditions
  作者：Reza Khalifeh、Zeinab Zarei、Maryam Rajabzadeh

  DOI：10.1039/d0nj05225f

  日期：——

  preparation of cyclic carbonates under optimized reaction conditions at 100 °C, 0.7 MPa and 1.6 mol% of the nanocatalyst. This reaction was conducted without using any metal, additive, toxic reagents and solvent/co-catalyst which provides mild and green conditions from the standpoint of green chemistry. Owing to having acidic-basic sites which can simultaneously accelerate the ring-opening of the epoxy ring

  成功引入了可重复使用，环保，长寿命和高效的纳米催化剂，咪唑基离子液体固定在功能化磁性水滑石上（Fe 3 O 4 / HT-IM，IM被称为咪唑基三聚氰胺）。合成的纳米催化剂的结构通过几种技术来表征，所述技术显示出具有约50nm的平均粒径的板状形状以及酸性位点的存在（位点密度：12mmol g -1）。Fe 3 O 4的催化活性在优化的反应条件下，于100°C，0.7 MPa和1.6 mol％的纳米催化剂的条件下，在二氧化碳的化学固定反应中制备环状碳酸酯时探索了/ HT-IM。该反应不使用任何金属，添加剂，有毒试剂和溶剂/助催化剂进行，该反应从绿色化学的角度来看提供温和的绿色条件。由于具有酸性碱性位点，可以同时加速环氧环的开环和CO 2的引入，该催化剂是有吸引力的并且适合该反应。特别地，所制备的催化剂可以使用外部磁场容易地分离并且可以重复使用六次以上，而没有催化性能和选择性上的任何显着损失。
• Design and synthesis of a new magnetic metal organic framework as a versatile platform for immobilization of acidic catalysts and CO₂ fixation reaction
  作者：Faezeh Taghavi、Amir Khojastehnezhad、Reza Khalifeh、Maryam Rajabzadeh、Fahimeh Rezaei、Khalil Abnous、Seyed Mohammad Taghdisi

  DOI：10.1039/d1nj02140k

  日期：——

  In this study, a new magnetic metal organic framework (MNP@MOF) with a core–shell structure has been introduced as an efficient and versatile platform for immobilization of Preyssler (H14[NaP5W30O110]) heteropolyacid (PR HPA). The chemical structure of the nanocatalyst was analyzed by using different techniques, including HRTEM, TEM, HRTEM mapping, SEM, EDX, TGA, XRD, VSM, BET and ICP. These analyses

  在这项研究中，引入了一种具有核壳结构的新型磁性金属有机骨架（MNP@MOF）作为固定 Preyssler（H 14 [NaP 5 W 30 O 110]) 杂多酸 (PR HPA)。通过使用不同的技术分析了纳米催化剂的化学结构，包括 HRTEM、TEM、HRTEM mapping、SEM、EDX、TGA、XRD、VSM、BET 和 ICP。这些分析证实了催化剂的核壳和球形结构以及 PR HPA 成功固定在其表面上。完成表征后，通过二氧化碳的化学固定来测试催化剂合成环状碳酸酯的效率。在无溶剂条件下，在 0.4 mol% 催化剂和 0.3 MPa CO 2压力的存在下，不同的环氧化物转化为环状碳酸酯。迄今为止，该反应已使用各种非均相催化剂进行，但这是首次报道使用 PR HPA 和 MNP@MOF 进行该反应。
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：ISIS INNOVATION

  公开号：WO2015004485A1

  公开（公告）日：2015-01-15

  The present invention relates to therapeutic compounds useful for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia). The compounds have the structural formula I shown below: wherein Q, X, p, R1, q, R3 and R4 are as defined herein. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, the use of these compositions for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia), and to processes for the preparation of the pharmaceutical compositions defined herein.

  本发明涉及治疗化合物，用于治疗神经退行性疾病、神经肌肉疾病和/或三联重复疾病（如弗里德雷希共济失调）。这些化合物具有下面显示的结构式I：其中Q、X、p、R1、q、R3和R4的定义如本文所述。本发明还涉及包含上述定义的化合物的药物组合物，以及利用这些组合物治疗神经退行性疾病、神经肌肉疾病和/或三联重复疾病（如弗里德雷希共济失调）的用途，以及用于制备上述药物组合物的过程。